Expanding the Depth and Breadth of
Oppenheimer's Biotech Equity Research
NEW
YORK, July 11, 2024 /PRNewswire/ -- Oppenheimer
& Co. Inc. (Oppenheimer) — a leading investment bank,
wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE:
OPY) — announced today the appointment of Andreas Argyrides as Executive Director and
Senior Analyst covering the Biotechnology sector.
"We are thrilled to have Andreas join our biotech research team
as we expand the depth and breadth of our industry expertise," said
John Hellier, Senior Managing Director, Head of Equities for
Oppenheimer. "He is well positioned to add value to Oppenheimer
clients, given his wide and varied experiences across the
healthcare industry."
Argyrides has more than 15 years of financial industry
experience. His expertise includes coverage of companies engaged in
the development of new therapies for eye, liver, and lung diseases
as well as gene therapies for rare genomic diseases.
"Andreas is an ideal complement to Oppenheimer's Biotech
research effort, and I look forward to working with him as we build
on our momentum," said William Bird,
Director of Equity Research and Head of Thematic Research. "Our
robust coverage capabilities have contributed to making Healthcare
Equity Research at Oppenheimer among the most trusted team of
analysts in the industry."
"Breakthroughs in biotechnology therapies have the potential to
save lives and improve the condition of countless patients,"
Argyrides said. "Investors need access to reliable information in
order to capitalize on opportunities in the sector. That's why I am
excited to join Oppenheimer, an institution that I have long
admired for its insightful commentary and strong reputation within
the Healthcare space."
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc.
(Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc.
(OPY on the New York Stock Exchange), and its affiliates provide a
full range of wealth management, securities brokerage and
investment banking services to high net-worth individuals,
families, corporate executives, local governments, businesses and
institutions.
Media Contact:
Joseph
Kuo / Michael Dugan
Haven Tower Group LLC
424 317 4851 or 424 317 4852
jkuo@haventower.com or mdugan@haventower.com
View original
content:https://www.prnewswire.com/news-releases/oppenheimer--co-inc-appoints-andreas-argyrides-as-executive-director-and-senior-analyst-covering-the-biotechnology-sector-302193080.html
SOURCE Oppenheimer & Co. Inc.